|
Market Closed -
NYSE
04:00:03 12/09/2026 HKT
|
5-day change | 1st Jan Change | ||
| 160.17 USD | +0.33% |
|
-1.56% | +74.23% |
| 09-12 | AstraZeneca Says Late-Stage Etcamah Breast-Cancer Trial Misses Main Goal | MT |
| 09-12 | AstraZeneca's breast cancer pill fails in late-stage trial | RE |
| Market Cap | 246B 212B 200B 182B 341B 23,461B 342B 2,379B 915B 11,936B 922B 902B 37,717B | P/E 2026 * |
20.3x | P/E 2027 * | 17.7x |
|---|---|---|---|---|---|
| Enterprise Value | 265B 228B 216B 196B 368B 25,319B 370B 2,568B 987B 12,881B 995B 973B 40,704B | EV / Sales 2026 * |
4.19x | EV / Sales 2027 * | 3.85x |
| Free-Float |
96.63% | Yield 2026 * |
2.11% | Yield 2027 * | 2.25% |
Last Transcript : AstraZeneca PLC
| 1 day | +0.33% | ||
| Current month | +72.65% | ||
| Current year | +74.23% |
| Current year | 89.04 |  | 161.51 |
| 1 year | 72.9 | | 161.51 |
| 3 years | 60.47 | | 161.51 |
| 5 years | 52.65 | | 161.51 |
| 10 years | 25.55 | | 161.51 |
| Manager | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 66 | 01/10/2012 |
Aradhana Sarin
DFI | Director of Finance/CFO | 52 | 01/08/2021 |
Jeffrey Pott
CMP | Compliance Officer | - | 01/01/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 70 | 06/04/1999 | |
Pascal Soriot
BRD | Director/Board Member | 66 | 01/10/2012 |
Philip Broadley
BRD | Director/Board Member | 65 | 27/04/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.33% | -1.56% | - | - | 246B | |
| -0.65% | -2.93% | +47.70% | +86.17% | 994B | |
| -0.29% | -3.51% | +49.15% | +62.35% | 640B | |
| +0.83% | +0.26% | +17.76% | +72.25% | 454B | |
| -0.38% | -3.59% | +30.13% | +35.17% | 337B | |
| -0.09% | -13.54% | +13.34% | +24.95% | 261B | |
| -0.43% | -2.48% | -0.73% | +9.58% | 246B | |
| -1.34% | -13.70% | +36.53% | +44.96% | 204B | |
| -3.44% | -7.51% | -20.63% | -59.44% | 190B | |
| -0.75% | -4.82% | +25.46% | +87.14% | 178B | |
| Average | -0.62% | -5.76% | +22.08% | +40.35% | 389.42B | |
| Weighted average by Cap. | -0.45% | -4.42% | +30.96% | +54.95% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 63.3B 54.54B 51.64B 46.81B 87.81B 6,047B 88.26B 613B 236B 3,077B 238B 233B 9,722B | 66.9B 57.64B 54.58B 49.47B 92.81B 6,391B 93.28B 648B 249B 3,252B 251B 246B 10,274B |
| Net income | 12.03B 10.36B 9.81B 8.89B 16.68B 1,149B 16.77B 117B 44.81B 585B 45.17B 44.17B 1,847B | 13.77B 11.86B 11.23B 10.18B 19.1B 1,315B 19.2B 133B 51.3B 669B 51.7B 50.57B 2,114B |
| Net Debt | 19.45B 16.76B 15.87B 14.38B 26.98B 1,858B 27.12B 188B 72.47B 945B 73.05B 71.44B 2,987B | 11.77B 10.14B 9.6B 8.7B 16.32B 1,124B 16.41B 114B 43.84B 572B 44.19B 43.22B 1,807B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/09/26 | US$160.17 | +0.33% | 2,229,337 |
| 10/09/26 | US$159.64 | +1.72% | 2,935,497 |
| 09/09/26 | US$156.94 | -1.94% | 3,874,039 |
| 08/09/26 | US$160.04 | -1.63% | 5,146,270 |
| 04/09/26 | US$162.70 | -1.26% | 3,073,349 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- AZN Stock
- AZN Stock
Select your edition
All financial news and data tailored to specific country editions
